Cited by 576COVID-19 Clinical Research StudiesViral Infections and Immunology ResearchTakotsubo Cardiomyopathy and Associated Phenomena

Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome

Open access
Hendren, Nicholas S., Drazner, Mark H., Bozkurt, Biykem, Cooper, Leslie T.·2020·Circulation

Abstract

Coronavirus disease 2019 (COVID-19) is a rapidly expanding global pandemic caused by severe acute respiratory syndrome coronavirus 2, resulting in significant morbidity and mortality. A substantial minority of patients hospitalized develop an acute COVID-19 cardiovascular syndrome, which can manifest with a variety of clinical presentations but often presents as an acute cardiac injury with cardiomyopathy, ventricular arrhythmias, and hemodynamic instability in the absence of obstructive coronary artery disease. The cause of this injury is uncertain but is suspected to be related to myocarditis, microvascular injury, systemic cytokine-mediated injury, or stress-related cardiomyopathy. Although histologically unproven, severe acute respiratory syndrome coronavirus 2 has the potential to directly replicate within cardiomyocytes and pericytes, leading to viral myocarditis. Systemically elevated cytokines are also known to be cardiotoxic and have the potential to result in profound myocardial injury. Prior experience with severe acute respiratory syndrome coronavirus 1 has helped expedite the evaluation of several promising therapies, including antiviral agents, interleukin-6 inhibitors, and convalescent serum. Management of acute COVID-19 cardiovascular syndrome should involve a multidisciplinary team including intensive care specialists, infectious disease specialists, and cardiologists. Priorities for managing acute COVID-19 cardiovascular syndrome include balancing the goals of minimizing healthcare staff exposure for testing that will not change clinical management with early recognition of the syndrome at a time point at which intervention may be most effective. This article aims to review the best available data on acute COVID-19 cardiovascular syndrome epidemiology, pathogenesis, diagnosis, and treatment. From these data, we propose a surveillance, diagnostic, and management strategy that balances potential patient risks and healthcare staff exposure with improvement in meaningful clinical outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.120.047349

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hendren, N. S., Drazner, M. H., Bozkurt, B., & Cooper, L. T.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Michael E. DeBakey VA Medical Center (US)
  • Mayo Clinic in Florida (US)
Corresponding author
Cooper, Leslie T.
Venue
Circulation
Published
2020-06-09
Volume
141
Issue
23
Pages
1903-1914
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3016959086
Cited by
576
References
74
Citations by year
2026: 6 · 2025: 20 · 2024: 24 · 2023: 58 · 2022: 117 · 2021: 183 · 2020: 165 · 2018: 1 · 2013: 1
FWCI
6.18
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Takotsubo Cardiomyopathy and Associated Phenomena
Keywords
COVID-19 pandemic, myocarditis, cardiomyopathy, ventricular arrhythmias, hemodynamic instability, takotsubo cardiomyopathy, IL-6 inhibitors, convalescent serum, antiviral therapy, healthcare worker exposure, surveillance strategy, diagnosis, management
MeSH terms
Cytokine Release Syndrome, Angiotensin-Converting Enzyme 2, COVID-19, Interleukin-6 Inhibitors, COVID-19 Serotherapy, Antiviral Agents, Arrhythmias, Cardiac, Cardiovascular Diseases, Hemodynamics, Humans, Immunization, Passive, Peptidyl-Dipeptidase A, Myocarditis, Organ Specificity, Pneumonia, Viral, Receptors, Virus, Risk Factors, Serine Endopeptidases, Biomarkers, Interleukin-6, Cytokines, Immunoglobulins, Intravenous, Infectious Disease Transmission, Patient-to-Professional, Coronavirus Infections, Disease Management, Severe Acute Respiratory Syndrome, Viral Tropism, Pandemics, Molecular Targeted Therapy, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review